Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y.
Behr SC, et al. Among authors: noworolski sm.
J Nucl Med. 2019 Jul;60(7):910-916. doi: 10.2967/jnumed.118.220715. Epub 2018 Nov 21.
J Nucl Med. 2019.
PMID: 30464040
Free PMC article.
Clinical Trial.